Active, Not Recruiting
Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies - CA224-022
Updated: 14 October, 2019 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - For dose escalation monotherapy: CLL, HL, NHL, MM - For dose expansion monotherapy: CLL, HL, NHL - For dose escalation and dose expansion in combination with BMS-936558: HL and DLBCL - Progressed, or been intolerant to, at least one standard treatment regimen - Not eligible for or declined transplantation or any standard therapy known to be life prolonging or life saving - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - At least 1 lesion with measurable disease at baseline - Availability of an existing tumor biopsy sample (or consent to allow pre-treatment tumor biopsy if sample not available) Exclusion Criteria: - Known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease (controlled CNS metastases are allowed) - Autoimmune disease - Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent - Uncontrolled or significant cardiovascular disease Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
